10x Genomics Inc - Class A risk profile
44 Elevated one input has moved against it
Measured 21 October 2026 from TXG's filed statements. Recomputed nightly.
44 (Elevated), driven by Competitive position at 61, over 5 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 60 | Stretched | Volatile | One-year price volatility — 74.4% |
| Operating pressure | Reads cost_of_revenue, operating_expense, operating_income and revenue. No reading is stored for this company. | |||
| Cash conversion | 12 | Contained | Easing | Capital spending against operating cash — 0.04x |
| Leverage and coverage | 1 | Contained | Easing | Current ratio — 4.46x |
| Competitive position | 61 | Stretched | Stable | Operating-margin gap against peers — -21.3 percentage points |
| Concentration | 49 | Elevated | Stable | Geographic concentration — 3,727 HHI |
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Healthcare companies with a risk reading
Lilly(Eli) & Company 33Johnson & Johnson 39Abbvie Inc 57Unitedhealth Group Inc 43Roche Holding AG 35Merck & Co Inc 35Novartis AG 29Novartis AG 31Astrazeneca plc 33Thermo Fisher Scientific Inc 44AMGEN Inc 47Gilead Sciences Inc 51
Financials, valuation and price history for 10x Genomics Inc - Class A